Nkarta, Inc. Common Stock (NKTX) is a publicly traded Healthcare sector company. As of May 21, 2026, NKTX trades at $2.80 with a market cap of $191.74M and a P/E ratio of -1.97. NKTX moved +4.10% today. Year to date, NKTX is +47.37%; over the trailing twelve months it is +55.56%. Its 52-week range spans $1.31 to $4.76. Analyst consensus is strong buy with an average price target of $12.50. Rallies surfaces NKTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nkarta Extends Cash Runway to 2029 with $266.7M, Expands Outpatient Dosing: Nkarta secured FDA agreement to allow outpatient dosing, re-dosing, and removal of overnight monitoring, and expanded Ntrust-2 to include rheumatoid arthritis. Nkarta held $266.7M in cash and investments at March 31, funding operations into 2029 after reporting $25M R&D, $5.9M G&A expenses and a $27.8M Q1 net loss.
| Metric | Value |
|---|---|
| Price | $2.80 |
| Market Cap | $191.74M |
| P/E Ratio | -1.97 |
| EPS | $-1.41 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.76 |
| 52-Week Low | $1.31 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-104.08M |
| Gross Margin | 0.00% |
5 analysts cover NKTX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.50.